Asimov, a synthetic biology company focused on therapeutic design and manufacturing, has entered into a licensing agreement with RevOpsis Therapeutics. RevOpsis specializes in developing next-generation multispecific biologics for ophthalmic therapies. This partnership stems from a successful cell line development campaign…
R&D World Max Jaderberg, president of Isomorphic Labs. Credit: Isomorphic Labs AI will eventually design every drug, predicts Max Jaderberg, president of Isomorphic Labs, a drug-discovery company spun out of Google DeepMind that remains under Alphabet’s control. Its programs…
The round's core claim is that the AI drug discovery field has not stalled because its models are bad. It has stalled because the data those models train on is finite, biased toward commercially attractive disease targets, and increasingly exhausted.
Western Australia's (WA) biomedical sector was on show at AusBiotech 2026, with a delegation of 19 WA companies and organisations attending Australia's premier biotechnology conference in Queensland from 21 to 23 October. Led by the Department of Energy and Economic Diversification in collaboration with…
HuBMAP Data Portal, Announced in Paper in Nature Communications, Links Over 9,000 Data Sets for Investigations of Human Body in 3D, and Scales from Organs to Cells Future goals for the HuBMAP Data Portal include further development to make it and its…
Scientists isolated three novel cytochalasins from an oyster-derived fungus, with two compounds curbing nitric oxide production in mouse microglial cells. Subject of Research: Discovery of novel cytochalasin compounds from an oyster-derived fungus with nitric oxide inhibitory activity in microglial cells…
A view inside SK Biopharmaceuticals’ research and corporate headquarters in Pangyo, Seongnam, Gyeonggi Province / Courtesy of SK Biopharmaceuticals SK Biopharmaceuticals, a Korean firm focused on developing original prescription drugs, has built a massive artificial intelligence (AI) dataset of more than…
Bioengineer.org Machines Join the Hunt for New Schistosomiasis Drugs Subject of Research: How automation and machine learning can accelerate drug discovery for schistosomiasis, a neglected tropical disease treated with a single decades-old drug. Article Title: Automation and machine learning…
By Brian Buntz | November 5, 2026 In a Nov. 4 interview with R&D World, Schnall-Levin predicted that some parts of developing therapies and diagnostics “will get massively accelerated” while others “will still be really painfully slow.” He is still working out which…
Targets, biomarkers, AI discovery, and Phases I–III clinical results.
An article joins this feed when it matches these terms. Each one is also a search of its own.